LONDON, ONTARIO, CANADA & AMSTERDAM, NETHERLANDS, July 30, 2025
New Drug Offers Hope for Debilitating Crohn’s Symptom
Mirikizumab significantly improved bowel urgency in Crohn’s patients.
Feeling that sudden, desperate urge to go to the bathroom is a miserable reality for many with Crohn’s disease. Now, a new analysis suggests a promising treatment might finally offer relief. Mirikizumab, a targeted therapy, has demonstrated the ability to provide early and lasting control over bowel urgency, a symptom often overlooked but profoundly life-disrupting for those with moderate-to-severe Crohn’s.
What is bowel urgency in Crohn’s?
This debilitating symptom, characterized by an intense and often uncontrollable need to defecate, significantly impacts daily life. Researchers found that this symptom strongly correlated with disease activity and abdominal pain in patients.
VIVID-1 Trial Shows Significant Improvements
The findings stem from an analysis of the phase 3 VIVID-1 trial, which evaluated bowel urgency outcomes in adults struggling with moderate-to-severe Crohn’s. These patients had previously not responded well to or could not tolerate conventional therapies or existing biologic treatments. They were randomly assigned to receive either mirikizumab or a placebo.
Mirikizumab was administered intravenously at 900 mg every four weeks for an initial 12-week induction period. This was followed by a maintenance phase where patients received 300 mg via subcutaneous injection every four weeks through week 52. Bowel urgency was meticulously tracked using the validated Urgency Numeric Rating Scale (NRS), where scores range from 0 (no urgency) to 10 (worst possible urgency). Assessments occurred at the trial’s start and every four weeks thereafter.
- Mirikizumab improved bowel urgency significantly compared to placebo.
- Relief was observed as early as week 6 and sustained through week 52.
- Patients with moderate-to-severe bowel urgency showed greater benefits.
- Urgency improvement at 12 weeks predicted better long-term outcomes.
Key Findings from the Analysis
The study involved 778 patients. Of these, 579 received mirikizumab, and 199 received a placebo. The average age for both groups was around 36 years, with women making up about 42.7% of the mirikizumab group and 40.7% of the placebo group.
At the beginning of the trial, a significant majority of participants experienced bowel urgency. Specifically, 94.2% had an Urgency NRS score of 3 or higher, and 65.9% scored 6 or higher. The data revealed a clear link: higher Crohn’s disease activity index scores and increased abdominal pain were associated with worse bowel urgency.
Mirikizumab demonstrated a significant advantage over placebo in improving bowel urgency. These positive effects were noticeable as early as week 6 and continued to be evident through the entire 52-week study period. Patients who started with a baseline Urgency NRS score of 3 or higher saw significantly higher rates of both clinically meaningful improvement (at least a 3-point reduction in NRS) and remission (NRS score of 2 or lower) at both 12 and 52 weeks compared to those on placebo. However, the difference between mirikizumab and placebo was not statistically significant for patients who began with a baseline Urgency NRS of 6 or higher.
Importantly, achieving a clinically meaningful improvement in bowel urgency by week 12 was linked to better overall clinical outcomes and endoscopic results at both the 12-week and 52-week marks.
Implications for Clinical Practice
The study authors emphasized the critical need to assess bowel urgency in Crohn’s disease patients. “This study highlights the importance of assessing [bowel urgency] in [Crohn’s disease] and provides valuable information for [healthcare providers] when considering appropriate [bowel urgency] management, regardless of disease activity control,” they stated. This suggests that addressing urgency should be a priority in patient care, irrespective of other disease markers.
Study Limitations and Considerations
The researchers acknowledged certain limitations. The Urgency NRS score is inherently subjective and can vary between individuals and over time. Furthermore, the trial participants were predominantly White or Asian, which may limit the generalizability of the findings to more diverse populations. The frequency of clinical visits in a trial setting might also differ from real-world patient care.
This research was funded by Eli Lilly and Company, with several authors being employees and shareholders of the company. Other authors reported financial ties to various pharmaceutical companies, including the funding agency.
